APA (7th ed.) Citation

Postel-Vinay, S., Italiano, A., Martin Romano, P., Cassier, P., Siu, L., Lossos, I., . . . Gounder, M. (2022). 456MO METEOR-1: A phase I study of the safety and efficacy of the protein arginine methyltransferase 5 (PRMT5) inhibitor GSK3326595 in advanced solid tumors. Annals of Oncology, 33, S746. https://doi.org/10.1016/j.annonc.2022.07.585

Chicago Style (17th ed.) Citation

Postel-Vinay, S., et al. "456MO METEOR-1: A Phase I Study of the Safety and Efficacy of the Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor GSK3326595 in Advanced Solid Tumors." Annals of Oncology 33 (2022): S746. https://doi.org/10.1016/j.annonc.2022.07.585.

MLA (9th ed.) Citation

Postel-Vinay, S., et al. "456MO METEOR-1: A Phase I Study of the Safety and Efficacy of the Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor GSK3326595 in Advanced Solid Tumors." Annals of Oncology, vol. 33, 2022, p. S746, https://doi.org/10.1016/j.annonc.2022.07.585.